{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:54:36Z","timestamp":1783475676567,"version":"3.55.0"},"reference-count":5,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Dermatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Public interest in Janus kinase (JAK) inhibitors for alopecia areata increased following media coverage and the 2022 US Food and Drug Administration (FDA) approval of baricitinib, highlighting the need for patient education and physician guidance on appropriate indications and treatment selection for hair loss disorders.<\/jats:p>","DOI":"10.2196\/75119","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T14:50:07Z","timestamp":1773499807000},"page":"e75119-e75119","source":"Crossref","is-referenced-by-count":1,"title":["Public Interest in Janus Kinase (JAK) Inhibitors for Alopecia Areata: A Google Trend Analysis"],"prefix":"10.2196","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6787-7804","authenticated-orcid":false,"given":"Jade","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4863-2480","authenticated-orcid":false,"given":"Nourine A H","family":"Kamili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1871-0921","authenticated-orcid":false,"given":"Hala","family":"Idris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-8356","authenticated-orcid":false,"given":"Loren D","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"issue":"24","key":"R1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28248064","article-title":"Novel Janus kinase inhibitors in the treatment of dermatologic conditions","volume":"28","author":"Rygu\u0142a","journal-title":"Molecules"},{"issue":"9","key":"R2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the treatment of alopecia areata","volume":"83","author":"Freitas","journal-title":"Drugs (Abingdon Engl)"},{"issue":"2","key":"R3","doi-asserted-by":"publisher","DOI":"10.2196\/13439","article-title":"Google Trends in infodemiology and infoveillance: methodology framework","volume":"5","author":"Mavragani","journal-title":"JMIR Public Health Surveill"},{"key":"R4","unstructured":"Abdelmalek M . New drug for alopecia shows promise: what you need to know. ABC News. 2019. URL: https:\/\/abcnews.com\/GMA\/Wellness\/drug-alopecia-shows-promise\/story?id=60128818&utm_source=chatgpt.com [Accessed 11-05-2024]"},{"issue":"10","key":"R5","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s13555-025-01517-9","article-title":"Evaluating current and emergent JAK inhibitors for alopecia areata: a narrative review","volume":"15","author":"Sanchez","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["JMIR Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/derma.jmir.org\/2026\/1\/e75119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:06:02Z","timestamp":1782842762000},"score":1,"resource":{"primary":{"URL":"https:\/\/derma.jmir.org\/2026\/1\/e75119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":5,"URL":"https:\/\/doi.org\/10.2196\/75119","relation":{},"ISSN":["2562-0959"],"issn-type":[{"value":"2562-0959","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"article-number":"v9i24e75119"}}